A benzamide is an amide derivative of benzoic acid — a benzene ring bonded directly to a carboxamide group — and is a chemical scaffold rather than a single pharmacological class. Membership is defined by this aromatic amide core, not by a shared receptor target; substances built on the scaffold span selective dopamine D2/D3 antagonist antipsychotics, antiemetics, and — for the members covered here — synthetic opioid analgesics.[1]
The members documented on this page, tianeptine and U-47700, illustrate one corner of that chemistry space: compounds that converge on mu-opioid receptor agonism rather than the D2/D3 antagonism of older benzamide antipsychotics such as sulpiride, amisulpride, and metoclopramide. Tianeptine's scaffold is technically a dibenzothiazepine, grouped here for its aromatic amide-adjacent system.[2]
The two members' dose–response trajectory tracks the opioid class: low-to-moderate exposures produce analgesia, anxiolysis, mild euphoria, and sedation; higher exposures produce stupor and dose-dependent respiratory depression.[3] Tianeptine has been used clinically as an antidepressant outside the United States and widely abused there as an unregulated supplement; U-47700 has only ever circulated in illicit recreational markets and was scheduled in the United States in 2016.
Pharmacology
Despite divergent scaffolds, the two listed members converge on the same downstream endpoint — activation of mu-opioid receptor (MOR) signalling in pain, reward, and brainstem respiratory circuitry.[4][3]
| Mechanism | Representative members | How it reaches the shared endpoint |
|---|---|---|
| Selective high-potency MOR agonism | U-47700 | Direct activation of mu-opioid receptors with negligible delta- or kappa-receptor activity |
| Moderate-potency MOR agonism with secondary DOR activity | tianeptine | Full agonism at mu (primary) and delta (secondary) receptors, with proposed secondary glutamatergic modulation |
MOR agonism, not D2/D3 antagonism, is the pharmacological commonality that organises this page. Tianeptine's antidepressant and anxiolytic behavioural effects in rodents require a functional MOR — knockout animals do not respond — and tianeptine also activates delta-opioid receptors at lower potency while being inactive at kappa.[5][4]
U-47700 is a selective, high-potency MOR agonist with negligible delta- or kappa-receptor activity; preclinical work places its analgesic potency at several-fold that of morphine, attributed to high lipophilicity and rapid CNS penetration.[3] Glutamatergic modulation has been proposed as a secondary mechanism for tianeptine's neuroplastic effects, but MOR activation drives the psychoactive and abuse-liability profile of both members.[2]
Substances
The two members documented here illustrate two distinct origins for a benzamide-scaffold opioid agonist: one a clinically approved antidepressant later recognised as an opioid, the other a research compound diverted from the medicinal-chemistry literature into illicit markets.
| Member | Subgroup | Role / distinctive feature |
|---|---|---|
| Tianeptine | Dibenzothiazepine (amide-adjacent) | Approved antidepressant in several countries; the short half-life of its sodium salt drives rapid compulsive redosing in abuse contexts[6] |
| U-47700 | 3,4-dichlorobenzamide | Never approved for human use; originated in an Upjohn medicinal-chemistry series in the 1970s–1980s and entered illicit recreational markets around 2015[1] |
These members differ widely in their clinical histories and chemical specifics, but each contributes opioid load through the same receptor pathway.
Subjective Effects
Across both members the experiential profile is that of the opioid class, with deepening MOR activation tracking exposure.
| Exposure | Characteristic effects |
|---|---|
| Low | Mild analgesia, anxiolysis, a sense of warmth and well-being, slowed gastrointestinal motility |
| Moderate–high | Pronounced euphoria, sedation, cognitive impairment, slurred speech, loss of motor coordination, pupil constriction |
| High | Stupor, dose-dependent respiratory depression, hypotension, cyanosis, loss of consciousness, apnea |
The same axis — MOR-mediated CNS depression — drives both the sought euphoria and anxiolysis and the lethal respiratory suppression, and the margin between them narrows as exposure rises.[3] Tianeptine's short half-life can compress that margin further, with repeated doses over hours blurring the line between desired effect and inadvertent overexposure.[6]
Safety
Risk profile
The defining acute danger of these substances is mu-opioid-mediated respiratory depression. Both listed members suppress brainstem respiratory drive in a dose-dependent fashion. Combining them with other CNS depressants — benzodiazepines, alcohol, or other opioids — sharply amplifies overdose risk and is the dominant pattern in documented fatalities.[3]
U-47700 fatalities have been documented in forensic literature since 2016 and predominantly involve polydrug contexts.[3] Tianeptine overdose produces the same respiratory depression phenotype, and US poison-control exposures have risen sharply since the mid-2010s, with coma and death among reported outcomes.[7]
Naloxone reverses the opioid effects of both members. Case reports describe successful naloxone reversal of U-47700-induced unconsciousness,[3] and standard opioid-overdose emergency management — airway support, naloxone, and monitoring for re-narcotisation as naloxone wears off — applies to tianeptine overdose as well. The acute clinical picture is the canonical opioid one: pinpoint pupils, slowed or absent respirations, hypotension, bradycardia, and cyanosis.
Tolerance & dependence
Tolerance to MOR-mediated analgesia, euphoria, and respiratory depression develops with regular use of both members, in line with the broader opioid class. Cross-tolerance between members, and with other mu-opioid agonists, is expected by shared mechanism.
Physical dependence is well documented for tianeptine. The short half-life of the sodium salt compresses the dependence timeline, and a 2025 systematic review found that roughly 58% of cases in the tianeptine misuse literature met criteria for opioid-type habitual misuse.[6] Withdrawal is described as resembling or exceeding the severity of classical opioid withdrawal — agitation, nausea, diarrhoea, tachycardia, hypertension, diaphoresis, tremor, and dysphoria.[6] For U-47700, documented human withdrawal cases are sparse — the literature is dominated by overdose fatalities — but its high MOR potency and efficacy predict strong dependence by class mechanism.[3]
Withdrawal from tianeptine can be severe. Reported syndromes resemble or exceed classical opioid withdrawal in intensity, and the short half-life accelerates onset. People physically dependent should not attempt abrupt cessation without clinical guidance; a supervised, medically managed approach is the established standard.[6]
Recovery
Recovery from dependence on these substances follows the well-established opioid use disorder framework. Buprenorphine–naloxone has been reported effective for managing tianeptine use disorder, reducing withdrawal symptoms and supporting abstinence;[6] the broader medications-for-opioid-use-disorder toolkit — buprenorphine, methadone, and naltrexone — is the standard of care. A clinician or addiction medicine service can structure a safe withdrawal plan and connect to ongoing treatment.
Recovery resources, crisis lines, and support pathways → View all
Members
references
- [1]^abcKyei-Baffour K, Lindsley CW (2020) DARK Classics in Chemical Neuroscience: U-47700 — ACS Chemical Neuroscience doi:10.1021/acschemneuro.0c00330
- [2]^abNishio Y, Lindsley CW, Bender AM (2024) Classics in Chemical Neuroscience: Tianeptine — ACS Chemical Neuroscience doi:10.1021/acschemneuro.4c00519
- [3]
- [4]^abGassaway MM, Rives ML, Kruegel AC, Javitch JA, Sames D (2014) The atypical antidepressant and neurorestorative agent tianeptine is a mu-opioid receptor agonist — Translational Psychiatry doi:10.1038/tp.2014.30
- [5]^Samuels BA, Nautiyal KM, Kruegel AC, Levinstein MR, Magalong VM, Gassaway MM, et al. (2017) The Behavioral Effects of the Antidepressant Tianeptine Require the Mu-Opioid Receptor — Neuropsychopharmacology doi:10.1038/npp.2017.60
- [6]